Not Yet Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm
NCT07372807
Ripertamab for the Treatment of Myasthenia Gravis (RIPERT-MG)
Safety and Efficacy of Ripertamab in Generalized Myasthenia Gravis
Sponsor: Zhongming Qiu
Conditions
Myasthenia Gravis (MG)
Interventions
ripertamab
Updated 1 time since 2026 Last updated: Jan 19, 2026 Started: Feb 28, 2026 Primary completion: Dec 31, 2027 Completion: Dec 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE1/PHASE2 clinical study on Myasthenia Gravis (MG), this trial is actively recruiting participants. The trial is conducted by Zhongming Qiu and has accumulated 1 data snapshot since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE1/PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Zhongming Qiu
Data source: Xinqiao Hospital of Chongqing
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.